国际妇产科学杂志

国际妇产科学杂志 ›› 2016, Vol. 43 ›› Issue (1): 70-74.

• 综述 • 上一篇    下一篇

抗血管生成药物联合化疗在复发性卵巢癌治疗中的研究进展

张洁，王晓慧   

  1. 730000 兰州，兰州大学第一临床医学院（张洁）；兰州大学第一医院妇产科（王晓慧）
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2016-02-15 发布日期:2016-02-15
  • 通讯作者: 王晓慧

Research Progress of the Combination of Antiangiogenic Agents and Chemotherapy for Recurrent Ovarian Cancer

ZHANG Jie，WANG Xiao-hui   

  1. The First Clinical Medical College of Lanzhou University，Lanzhou 730000，China（ZHANG Jie）；Department of Obstetrics and Gynecology，The First Hospital of Lanzhou University，Lanzhou 730000，China（WANG Xiao-hui）
  • Received:1900-01-01 Revised:1900-01-01 Published:2016-02-15 Online:2016-02-15
  • Contact: WANG Xiao-hui

PDF (PC)

5783

摘要： 卵巢癌是妇科常见的恶性肿瘤之一，其发生、发展及肿瘤细胞的浸润转移离不开新生血管，因此通过抑制肿瘤新生血管形成，是治疗卵巢癌的有效途径之一。目前主要研究的抗血管生成药物包括血管内皮生长因子抑制剂（如贝伐单抗）、酪氨酸激酶抑制剂（如索拉菲尼、帕唑帕尼、西地尼布等）和血管生成素抑制剂（如Trebananib）。大量的Ⅱ、Ⅲ期临床试验表明抗血管靶向药物联合化疗为复发性铂敏感性或铂耐药性卵巢癌的治疗带来了曙光，明显延长了疾病无进展生存期。综述不同抗血管靶向药物联合化疗治疗复发性卵巢癌的临床研究现状及最新进展。

关键词: 卵巢肿瘤, 抗肿瘤联合化疗方案, 抗血管生成药物, 贝伐单抗, 西地尼布, 复发性卵巢癌

Abstract: Ovarian cancer is one of the common gynecologic malignant tumors. The development of it and the metastases of tumor cells need new blood vessels. Therefore, by inhibiting tumor angiogenesis is one of effective ways to treat ovarian cancer. The main antiangiogenic agents included vascular endothelial growth factor inhibitor （such as Bevacizumab）, tyrosine kinase inhibitors （such as Sorafenib, Pazopanib and Cediranib）, and angiogenin inhibitor （such as Trebananib）. The combination of antiangiogenic targeted agents with chemotherapy has been shown to benefit patients with platinum-sensitive or platinum-resistant recurrent ovarian cancer by lots of phase Ⅱ and Ⅲ clinical trials. Meanwhile, combination with chemotherapy provided a clinically meaningful prolongation in progression-free survival. This paper reviewed clinical research status and the latest development with the combination of different antiangiogenic targeted agents and chemotherapy in patients with recurrent ovarian cancer.

Key words: Ovarian neoplasms, Antineoplastic combined chemotherapy protocols, Antiangiogenic agents, Bevacizumab, Cediranib, Recurrence ovarian cancer